Cycloserine did not increase depression incidence or severity at standard dosing for multidrug-resistant tuberculosis

In a longitudinal cohort of MDR-TB patients receiving individualised, DST-based treatment, neither the inclusion of cycloserine in a multidrug regimen nor the dose used (up to 750 mg daily) significantly increased incidence of depression during treatment https://bit.ly/3GtQmOH

Detalles Bibliográficos
Autores principales: Tornheim, Jeffrey A., Udwadia, Zarir F., Arora, Prerna R., Gajjar, Ishita, Gupte, Nikhil, Sharma, Samridhi, Karane, Megha, Sawant, Namrata, Kharat, Nisha, Blum, Alexander J., Shivakumar, Shri Vijay Bala Yogendra, Mullerpattan, Jai B., Pinto, Lancelot M., Ashavaid, Tester F., Gupta, Amita, Rodrigues, Camilla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Agora
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943271/
https://www.ncbi.nlm.nih.gov/pubmed/34949698
http://dx.doi.org/10.1183/13993003.02511-2021
Descripción
Sumario:In a longitudinal cohort of MDR-TB patients receiving individualised, DST-based treatment, neither the inclusion of cycloserine in a multidrug regimen nor the dose used (up to 750 mg daily) significantly increased incidence of depression during treatment https://bit.ly/3GtQmOH

Ejemplares similares